A5049554341- Genetic factors in colorectal cancer
- Colorectal Cancer Screening and Detection
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Lung Cancer Treatments and Mutations
- Cancer Risks and Factors
- Economic and Financial Impacts of Cancer
- Skin Protection and Aging
- Lung Cancer Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Colorectal Cancer Surgical Treatments
- Air Quality and Health Impacts
- Prostate Cancer Treatment and Research
- Gastric Cancer Management and Outcomes
- Nutritional Studies and Diet
- Lung Cancer Research Studies
- Health, Environment, Cognitive Aging
- Frailty in Older Adults
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Epigenetics and DNA Methylation
- Pancreatic and Hepatic Oncology Research
- Climate Change and Health Impacts
University of Calgary
2019-2025
Alberta Health Services
2019-2025
Foothills Medical Centre
2023-2024
Cancer Institute (WIA)
2022
University of Alberta
2022
BC Cancer Agency
2022
Queen's University
2017-2021
Institute for Community Health
2021
Canadian Cancer Society
2019
McMaster University
2019
The COVID-19 pandemic is suspected to have affected cancer care and outcomes among patients in Canada. In this study, we evaluated the impact of state emergency period during (Mar. 17 June 15, 2020) on diagnoses, stage at diagnosis 1-year survival Alberta.We included new diagnoses 10 most prevalent types from Jan. 1, 2018, Dec. 31, 2020. We followed up 2021. used interrupted time series analysis examine first COVID-19-related Alberta number diagnoses. multivariable Cox regression compare who...
Cancer is the leading cause of death in Canada and estimated annual spending associated with cancer approximately $7.5 billion. Projecting future burden essential for health planning evaluation. We aimed to estimate incidence 2042.Age-sex-region-specific data were obtained years 1983-2012 was projected from 2013 2042 top five sites. The modelling algorithm combined a mixture projection methods select best-fitted model. When chosen model produced by resulted estimates that not consistent...
Objective Germline pathogenic variants (PVs) in the DNA mismatch repair (MMR) genes and base excision gene MUTYH underlie hereditary colorectal cancer (CRC) polyposis syndromes. We evaluated robustness discriminatory potential of tumour mutational signatures CRCs for identifying germline PV carriers. Design Whole-exome sequencing formalin-fixed paraffin-embedded (FFPE) CRC tissue was performed on 33 MMR carriers, 12 biallelic 25 sporadic MLH1 methylated MMR-deficient (MMRd controls) 160...
INTRODUCTION: The incidence of early-onset colorectal cancer (eoCRC) has been increasing in North America. Debate remains as to whether the trends by topography, histology, stage, or mortality this population are amenable intervention from screening. METHODS: CRC (2000–2017) and (2000–2018) data were obtained Canadian Cancer Registry Vital Statistics. Annual percentage changes (APC) (topography histology) eoCRC estimated using joinpoint regression. Incidence late-stage (III IV) versus...
The association between red meat consumption and colorectal cancer has been rigorously examined. However, a more comprehensive understanding of how the intake unprocessed contributes to development early precancerous lesions, such as advanced adenomas (ACRAs), requires further investigation. We examined associations different types ACRAs in sample population 1083 individuals aged ≥ 50 years undergoing an initial screening colonoscopy Calgary, Alberta, Canada. Associations grams per day...
<p>Supplemental Table 1. Cancer site definitions based on those used in the Canadian Statistics (CCS) reports.</p>
<p>Supplemental Table 3. Relative risk of developing a subsequent primary cancer (SPC) based on age at the first (FPC) diagnosis. Standardized incidence ratios (SIR) and 95% confidence intervals are reported by FPC sex.</p>
<p>Supplemental Figure 3. Cumulative incidence functions for the risk of a site-specific subsequent primary cancer. incidences are presented secondary cancers (SPC) sites with five highest estimated risks at 10-years since time surviving first cancer (FPC). We present 12 most common FPC sites. Panel titles include total number given site.</p>
<p>Supplemental Figure 1. Risk of subsequent primary cancer development. Cumulative incidence curves for death (from any cause) or the development a (SPC) all survivors in Alberta (2004 to 2020), separately by sex. Risks are reported at 2, 5, 10, and 15 years.</p>
<p>Supplemental Figure 2. Number of cancer survivors over time by site. The number for each site based on the year first primary (FPC) diagnosis in Alberta (2004 to 2020). Cancer sites are ordered left-to-right total entire period. For site, bars from 2004 (lightest) 2020 (darkest). A minimum 6 months survival is required our definition survivors, so only cancers diagnosed between January and June were potentially eligible inclusion.</p>
<p>Supplemental Table 8. Risk of developing a subsequent primary cancer for survivors under 85. All first cancers diagnosed at age 85+ were excluded and all before 85 artificially censored if the survivor was still observation had not yet developed cancer, lost to follow-up, or deceased.</p>
<p>Supplemental Table 7. Standardized incidence ratios (SIR) and 95% confidence intervals for the risk of a different-site subsequent primary cancer (SPC) by income quartiles urban/rural location at time FPC diagnosis.</p>
<p>Supplemental Table 2. Risk of developing a subsequent primary cancer by follow-up period. Follow-up was broken into four contiguous periods from the start survival, defined as six months after diagnosis first cancer, until end follow-up. Observed and expected number cancers standardized incidence ratios with confidence intervals are reported according to site sex. Cells based on observed less than 10 were not reportable (NR) due guidelines for identifiable data in Alberta Cancer...
<p>Supplemental Table 5. Standardized incidence ratios (SIR) and 95% confidence intervals for the risk of a different-site subsequent primary cancer by year first diagnosis sex.</p>
<p>Supplemental Table 6. Risk of developing a subsequent primary cancer by follow-up period and year first diagnosis. Follow-up was broken into four contiguous periods from the start survival, defined as six months after diagnosis cancer, until end follow-up. Observed expected number cancers standardized incidence ratios with confidence intervals are reported according to site sex.</p>
<p>Supplemental Table 4. Risk of developing a subsequent primary cancer by follow-up period and age at diagnosis for the first cancer. Follow-up was broken into four contiguous periods from start survival, defined as six months after cancer, until end follow-up. Observed expected number cancers standardized incidence ratios with confidence intervals are reported according to site sex. Cells based on observed less than 10 were not reportable (NR) due guidelines identifiable data in...
<div>AbstractBackground:<p>Improvements in cancer control have led to a drastic increase survivors who may be at an elevated risk of developing subsequent primary cancers (SPC). In this study, we assessed the and patterns SPC development among 196,858 adult Alberta, Canada.</p>Methods:<p>We used data from Alberta Cancer Registry identify all first occurring between 2004 2020. A was considered as next different site. We estimated standardized incidence ratios (SIR) for...
479 Background: Cabozantinib is approved as a subsequent therapy for patients with metastatic renal cell carcinoma (mRCC) based on the METEOR trial. However, only 5% of in this trial received prior immunotherapy. Methods: We identified mRCC from IMDC who were treated cabozantinib second-line (2L) setting 2010 to 2023. These stratified by risk groups and first-line (1L) treatment. analyzed overall response rate (ORR), time next treatment (TTNT), duration (TD), survival (OS) performed...
To assess the current status of and factors associated with treatment intensification (TI) (with androgen receptor pathway inhibitors [ARPIs] and/or docetaxel) for metastatic castration-sensitive prostate cancer (mCSPC) in Canada. Retrospective analysis data 431 patients mCSPC from Alberta Prostate Cancer Research Initiative database (July 2014-March 2022). The primary objective was to patient proportion receiving TI, time factors. secondary exploratory objectives were evaluating TI patterns...
Canadian adolescents have some of the highest rates substance use in world. The etiology this phenomenon has not been fully explored, and one possible contextual determinant is involvement sport activities that foster risk-taking behaviors through physical social mechanisms. Using 2013-14 Health Behaviour School Aged Children (HBSC) study we therefore examined hypothesis a contemporary national sample adolescents. strength direction relationship between varied by gender substance, with team...